Skip to content

ERC Pharma

Active
Public limited companyfounded 2023active for 2 yearsRue Jean Sonet,Isnes 10, 5032 Gembloux, BelgiumKBO/BCE: BE 1002.131.150
Summary

The computed 12-month bankruptcy probability of ERC Pharma is 2.4% (moderate). The 2025 annual accounts show negative equity (-€231,937) and a net result of -€179,975. Its solvency ranks better than 10% of 9,664 sector peers (NACE 46, financial year 2025). The company has been active since 2023 and the Belgian Official Gazette contains no insolvency or warning signals.

Risk analysisFollow ReportCompare
ERC PharmaActiveChecked score 50/100
Risk analysis ReportCompare

Directors

Directors
No directors read yet: 1 of 2 Gazette acts processed. See the directors and other office holders in the KBO →

Owners and capital

Owners

1 owner

Chain of control

  1. ERC BELGIUM 100%
  2. ERC Pharma

Highest known parent: ERC BELGIUM. The sources do not say who stands above it.

Owners 1

Sources: the companies' annual accounts, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.

We would like to set cookies. That happens only with your consent. What we measure